Cautious. Gilead trades at 25.3× forward earnings with modest growth (39/100 Compounder Score) and moderate leadership alignment (74/100, driven by CEO equity ownership). The core vulnerability: HIV franchise faces LOE risk without visible pipeline replacement, while oncology (Yeskimab) execution remains unproven. Neither compounder score justifies current valuation given structural headwinds.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for GILD:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 51/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates GILD (GILD) at 51/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. Gilead trades at 25.3× forward earnings with modest growth (39/100 Compounder Score) and moderate leadership alignment (74/100, driven by CEO equity ownership). The core vulnerability: HIV franchise faces LOE risk without visible
GILD's current Stocky Verdict is 51/100, placing it in the "Cautious" band. This composite combines a 42/100 Compounder score, 74/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for GILD yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
GILD scores 74/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
GILD's Vulnerability Profile scores 67/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to GILD.
Sign up free and unlock the full analysis on GILD — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for GILD in the app.
